BERYL DRUGS LTD. - Statement Of Investor Complaints For The Quarter Ended September 2022
|
< Back
|
10 Oct 2022
|
<table border=''1''><tr bgcolor=''#d6d6d6''><th class=''TTRow_left''> No.of Investor complaints pending at the beginning of the quarter </th><th class=''TTRow''> No.of Investor complaints received during the quarter</th><th class=''TTRow''> No.of Investor complaints disposed of during the quarter </th><th class=''TTRow''> No.of Investor complaints unresolved at the end of the quarter </th></tr><tr><td class=''TTRow''>0</td><td class=''TTRow''>0</td><td class=''TTRow''>0</td><td class=''TTRow''>0</td></tr></table><table border=''1''><tr><td > <span style=''font-weight:bold''>Name of the Signatory </span> </td><td> :- </td><td>SANJAY SETHI</td></tr><tr><td ><span style=''font-weight:bold''>Designation </span></td><td> :- </td><td>Managing Director / Whole Time Director</td></tr></table>
|
View all announcements for BERYL DRUGS LTD.
|
Source:
BSE India
|